Telomeron Inc, a US-based company owned 90% by Exagon Industries Ltd and 10% by Gaia Inc (NASDAQ:GAIA), has made a significant breakthrough with its TELOS-SP technology. The company, established in 2016, focuses on developing technology strategies for molecular surface treatment.
Today, Telomeron Inc has announced that it has successfully modified active ingredient molecules targeted at the cosmeceutical and nutraceutical sectors using a new class of quasi-particles called Ignitons, generated through the interaction between laser photons and ions in a low-pressure plasma environment. This technology has been proven through clinical trials, showing a 40% increase in absorption factors in some cases.
Telomeron Inc is not limiting itself to anti-aging and cosmetic products but plans to extend its technology to the food, agro-technical, and zootechnical supplementation sectors.
To achieve this, the company plans to externalize formulation, manufacturing, and packaging, while internalizing the processing of the blend with proprietary technology and product sales & marketing activities. Exagon group has approached industrial and institutional investors for funding to further develop Telomeron Inc towards a structure capable of offering B2B embedding services and dedicated B2C product lines.
Exagon has engaged Arthur D Little USA and Europe to develop appropriate business plans, market analysis, and investor scouting and fundraising activities. The ultimate goal is to divest the majority of its Telomeron shares to institutional and industrial investors capable of supporting its development, with the aim of projecting Telomeron towards a future listing on the public market, increasing its value to at least US$2 billion. The technology is scalable and not retro-engineerable, giving Telomeron multiple advantages and opportunities for future growth in various industries.